Clearing Out the Myeloid Compartment to Drive Effector Cell Function, Demonstrating Clinical Mechanisms, & Benefit of Combination Therapies Targeting the CCL2 & CXCL12 Pathways

Time: 4:30 pm
day: Day One


• Outlining resistance mechanisms to therapies such as checkpoints and T cell therapies, and demonstrating tumor regression in resistant patients through combination therapy

• Deciphering the mechanisms through which myeloid cells drive resistance to other therapies, and showing restored anti-tumor function through blocking myeloid recruitment

• Deploying myeloid therapies to overcome resistance in synergy with immunotherapy to enhance efficacy whilst balancing toxicity vs. efficacy of combination therapies